Follow this preprint

Germline TYK2 mutation and cancer risk

James Yarmolinsky, Christopher I. Amos, Rayjean J. Hung, Victor Moreno, Kimberley Burrows, Karl Smith-Byrne, Joshua R. Atkins, Paul Brennan, Colon Cancer Family Registry (CCFR), Colorectal Cancer Transdisciplinary study (CORECT), Genetics and Epidemiology of Colorectal Cancer Consortium (GECCO), Prostate Cancer Association Group to Investigate Cancer Associated Alterations in the Genome (PRACTICAL) consortium, James D. McKay, Richard M. Martin, George Davey Smith
doi: https://doi.org/10.1101/2022.01.26.22269888
This article is a preprint and has not been peer-reviewed [what does this mean?]. It reports new medical research that has yet to be evaluated and so should not be used to guide clinical practice.

Article Information

doi 
https://doi.org/10.1101/2022.01.26.22269888
History 
  • January 29, 2022.
Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

Author Information

  1. James Yarmolinsky, PhD1,2,*,
  2. Christopher I. Amos, PhD3,
  3. Rayjean J. Hung, PhD4,5,
  4. Victor Moreno, PhD6,7,8,9,
  5. Kimberley Burrows, PhD1,2,
  6. Karl Smith-Byrne, DPhil10,
  7. Joshua R. Atkins, PhD11,
  8. Paul Brennan, PhD11,
  9. Colon Cancer Family Registry (CCFR),
  10. Colorectal Cancer Transdisciplinary study (CORECT),
  11. Genetics and Epidemiology of Colorectal Cancer Consortium (GECCO),
  12. Prostate Cancer Association Group to Investigate Cancer Associated Alterations in the Genome (PRACTICAL) consortium,
  13. James D. McKay, PhD11,
  14. Richard M. Martin, BMBS, PhD1,2,12 and
  15. George Davey Smith, FRS, MD, DSc1,2
  1. 1Medical Research Council Integrative Epidemiology Unit at the University of Bristol, Bristol, United Kingdom
  2. 2Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, United Kingdom
  3. 3Baylor College of Medicine, Houston, USA
  4. 4Lunenfeld-Tanenbaum Research Institute, Sinai Health, Toronto, Canada
  5. 5University of Toronto, Toronto, Canada
  6. 6Biomarkers and Susceptibility Unit, Oncology Data Analytics Program, Catalan Institute of Oncology (ICO), L’Hospitalet de Llobregat, Barcelona, Spain
  7. 7Colorectal Cancer Group, ONCOBELL Program, Bellvitge Biomedical Research Institute (IDIBELL), L’Hospitalet de Llobregat, Barcelona, Spain
  8. 8Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain
  9. 9Department of Clinical Sciences, Faculty of Medicine, University of Barcelona, Barcelona, Spain
  10. 10Cancer Epidemiology Unit, Oxford Population Health, University of Oxford
  11. 11Genomic Epidemiology Branch, International Agency for Research on Cancer (IARC/WHO), Lyon, France
  12. 12University Hospitals Bristol, NHS Foundation Trust, National Institute for Health Research Bristol Biomedical Research Centre, University of Bristol, Bristol, UK
  1. ↵*Corresponding author:
    James Yarmolinsky, PhD, MRC Integrative Epidemiology Unit, Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK, james.yarmolinsky{at}bristol.ac.uk
Back to top
Posted January 29, 2022.
Download PDF
Print/Save Options
Download PDFFull Text & In-line FiguresXML

Supplementary Material

Data/Code
Email
Germline TYK2 mutation and cancer risk
James Yarmolinsky, Christopher I. Amos, Rayjean J. Hung, Victor Moreno, Kimberley Burrows, Karl Smith-Byrne, Joshua R. Atkins, Paul Brennan, Colon Cancer Family Registry (CCFR), Colorectal Cancer Transdisciplinary study (CORECT), Genetics and Epidemiology of Colorectal Cancer Consortium (GECCO), Prostate Cancer Association Group to Investigate Cancer Associated Alterations in the Genome (PRACTICAL) consortium, James D. McKay, Richard M. Martin, George Davey Smith
medRxiv 2022.01.26.22269888; doi: https://doi.org/10.1101/2022.01.26.22269888
This article is a preprint and has not been peer-reviewed [what does this mean?]. It reports new medical research that has yet to be evaluated and so should not be used to guide clinical practice.
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area

Reviews and Context

0

Comment

0

TRIP Peer Reviews

0

Community Reviews

0

Automated Services

0

Blogs/Media

0

Author Videos

You can now receive automatic notifications when a preprint is revised, withdrawn, commented on, peer reviewed, or published in a journal. Select the events you would like to follow below and click "Submit". To see all of the preprints you are currently following, please go to the medRxiv Alerts Page.

Sign In to Follow this Preprint

We use cookies on this site to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies.